Physician profile
Haley Hodoval
NPI 1295367464
$4,637.05
in general payments reported to CMS, 2019-2025
27 companies · $89.44 in 2025
The $89.44 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,119 · 2022: $1,062 · 2023: $1,448 · 2024: $919 · 2025: $89.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,456.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.69 | 2021-2025 | |
| Novo Nordisk INC | $768.78 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $544.89 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals Lp | $365.71 | 2021-2024 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $294.89 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company Ltd. | $209.13 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $192.63 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $188.33 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $182.31 | 2021-2023 | |
| Pfizer INC. | $148.70 | 2021-2024 | |
| Astellas Pharma US INC | $129.05 | 2022-2024 | Veozah |
| Amgen INC. | $121.66 | 2022-2025 | Evenity, Otezla, Repatha |
| Exact Sciences Corporation | $107.00 | 2023-2024 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $102.91 | 2023-2024 | Horizant, Edarbyclor, Edarbyclor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.26 | 2021-2023 | Tradjenta, Synjardy, Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $66.64 | 2023-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $48.32 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $31.29 | 2021 | |
| Eyevance Pharmaceuticals LLC | $31.29 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $29.74 | 2023 | Livalo, Seglentis |
| Currax Pharmaceuticals LLC | $29.21 | 2022-2023 | Nexletol, Contrave, Nexlizet |
| Alkermes, INC. | $27.56 | 2024 | Vivitrol |
| Esperion Therapeutics, INC. | $24.61 | 2024 | Nexletol |
| Alvogen INC | $23.93 | 2024 | Teriparatide |
| Linus Health, INC. | $15.06 | 2023 | |
| Novartis Pharmaceuticals Corporation | $14.64 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Hodoval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.